Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Apr;51(4):1392-1399.
doi: 10.1007/s10803-020-04542-z.

Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study

Logan K Wink  1   2 , Debra L Reisinger  1 , Paul Horn  1   2 , Rebecca C Shaffer  1   2 , Kaela O'Brien  1 , Lauren Schmitt  1   2 , Kelli R Dominick  1   2 , Ernest V Pedapati  1   2 , Craig A Erickson  3   4
Affiliations
Randomized Controlled Trial

Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study

Logan K Wink et al. J Autism Dev Disord. 2021 Apr.

Abstract

Dysregulation of glutamate neurotransmission plays a critical role in autism spectrum disorder (ASD) pathophysiology and is a primary target for core deficit research treatment trials. The mechanism of action of ketamine has striking overlap with the theory of ASD as a disorder of synaptic communication and neuronal networks. This two-dose, double-blind, placebo controlled, cross-over pilot trial of intranasal (IN) ketamine targeting core social impairment included individuals with ASD (N = 21) between 14 and 29 years. Participants were randomized to received two doses of IN ketamine (30 and 50 mg) and two doses of matching placebo. No significant impact was noted on the Aberrant Behavior Checklist Social Withdraw subscale. The IN ketamine was well tolerated, with only transient mild adverse effects.

Keywords: Autism; Clinical trial; Ketamine.

PubMed Disclaimer

References

    1. Aan Het Rot, M., Zarate, C. A., Jr., Charney, D. S., & Mathew, S. J. (2012). Ketamine for depression: Where do we go from here? Biological Psychiatry, 72, 537–547. https://doi.org/10.1016/j.biopsych.2012.05.003 . - DOI - PubMed - PMC
    1. Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 5, 485–491.
    1. Anagnostou, E., Jones, N., Huerta, M., Halladay, A. K., Wang, P., Scahill, L., et al. (2015). Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder. Autism, 19(5), 622–636. - DOI
    1. Azari, P., Lindsay, D. R., Briones, D., Clarke, C., Buchheit, T., & Pyati, S. (2012). Efficacy and safety of ketamine in patients with complex regional pain syndrome: A systematic review. CNS Drugs, 26, 215–228. https://doi.org/10.2165/11595200-000000000-00000 . - DOI - PubMed
    1. Baio, J. (2012). Prevalence of Autism Spectrum Disorders: Autism and Developmental Disabilities Monitoring Network, 14 Sites, United States, 2008. Morbidity and Mortality Weekly Report. Surveillance Summaries. Volume 61, Number 3. Centers for Disease Control and Prevention.

Publication types